Vaxcyte, Inc. cash flow to debt ratio of -286.48% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Vaxcyte, Inc.'s free cash flow has decreased 40.89% from $-475.05M last year to $-669.29M, signaling decreasing performance

Vaxcyte, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

Vaxcyte, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.04 today, signaling weakened financials

Vaxcyte, Inc. has a net cash position, so leverage is healthy.

Vaxcyte, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Vaxcyte, Inc. has insufficient data to evaluate this check.

Vaxcyte, Inc.'s short-term assets of $1.63B exceed its short-term liabilities of $205.75M

Vaxcyte, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Vaxcyte, Inc.'s return on equity of -37.57%, is lower than 15.00%, indicating bad performance

Vaxcyte, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Vaxcyte, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Vaxcyte, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Vaxcyte, Inc. has negative free cash flow, indicating cash burn

Vaxcyte, Inc.'s yearly earnings has decreased 65.25% since last year from $-463.93M to $-766.63M, signaling decreasing performance

Vaxcyte, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -40.55% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Vaxcyte, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Vaxcyte, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Vaxcyte, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Vaxcyte, Inc. has insufficient data to evaluate this check.

Vaxcyte, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vaxcyte, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Vaxcyte, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Vaxcyte, Inc. has insufficient data to evaluate this check.

Vaxcyte, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vaxcyte, Inc. has a price-to-book ratio of 3.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Vaxcyte, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue